Regine Mayer‐Steinacker

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial

Ghazaleh Tabatabai, Isabel Ramirez, Beatrix Welte, Paula Bombach et autres

Leptomeningeal metastatic disease (LMD) of solid tumors represents a cancer stage with high unmet therapeutic need. Here we report results from the dose escalation part of a multicenter phase 1 trial investigating intraventricular nivolumab, now continuing in the expansion part. Eligible participants …

de (code pays fourni par la source)

Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome– paving the path towards precision medicine: a case report

Carolin Seeling, Sonja Dahlum, Ralf Marienfeld, Vera Jan et autres

BACKGROUND: Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional variants of the TP53 gene. Due to impaired DNA damage repair, conventional cytotoxic therapies or …

de (code pays fourni par la source)

SOP – Darmpassagestörung in der Palliativmedizin

Thomas J. Ettrich, Stefan S. Schönsteiner, Regine Mayer‐Steinacker, Stephan Stilgenbauer et autres

de (code pays fourni par la source)

Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients

Verena I. Gaidzik, Regine Mayer‐Steinacker, Mathias Wittau, Markus Schultheiß et autres

Desmoplastic small round blue cell tumor (DSRCT) is a highly aggressive fatal sarcoma without evidence‐based therapeutic guidelines. We present here seven patients with DSRCT including immunohistochemistry combined with fluorescence in situ hybridization (FISH), next generation sequencing (NGS, n = 6) as well …

de (code pays fourni par la source)

Prognostic factors for overall survival in elderly patients with glioblastoma: Analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial

Annika Malmström, Felix Boakye Oppong, Wolfgang Wick, Normand Laperrière et autres

Abstract Background The majority of patients diagnosed with glioblastoma are >60 years. Three randomized trials addressed the roles of radiotherapy (RT) and temozolomide (TMZ) for elderly patients. NORDIC and NOA-08 compared RT versus TMZ, while CE.6 randomized between hypofractionated RT and RT …

se, be, ca, de, ch, no, at (code pays fourni par la source)

Enhancing coping skills through brief interventions during cancer therapy – a quasi-experimental clinical pilot study

Norbert Gelse, Daniela Bodschwinna, Marc N. Jarczok, Magdalena Wanner et autres

Introduction Psycho-oncological interventions can reduce distress by activating individual resources and enhancing coping skills. Since medical cancer treatment is performed increasingly in outpatient settings, there is a growing need for evidence-based and brief interventions to be integrated seamlessly into these treatment procedures. …

de, ch (code pays fourni par la source)

Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project

Friederike Braulke, Servet Para, Bernd Alt‐Epping, Mitra Tewes et autres

PURPOSE: Guidelines recommend a structured symptom screening (SC) for especially advanced cancer patients (CPs). The aim of this multicenter German prospective quality assurance project KeSBa (Kennzahl Symptom- und Belastungserfassung) was to gain knowledge on SC procedures in Oncology Centers (OCs) for advanced …

de, ch (code pays fourni par la source)

Data Supplement from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway

Adrian von Witzleben, Lukas T. Goerttler, Ralf Marienfeld, Holger Barth et autres

Data Supplement from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway

Supplementary Table 4 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway

Adrian von Witzleben, Lukas T. Goerttler, Ralf Marienfeld, Holger Barth et autres

List of up and down regulated genes on expression level with a p-value of 10-4 a FC of 10.

Supplementary Figure 4C from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway

Adrian von Witzleben, Lukas T. Goerttler, Ralf Marienfeld, Holger Barth et autres

Expression data of mRNA as shown by box plot graphs for brachyury (A), collagen 2A1 (B) and CD24 (C).

Supplementary Figure 1 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway

Adrian von Witzleben, Lukas T. Goerttler, Ralf Marienfeld, Holger Barth et autres

Overview ideogram of CGH data of all chordoma cell lines. Every cell line corresponds to one color. Lines on the left side are losses, and on the right side are gains of chromosomal material. Arrows mark the CDK6 region on 7q and …

Supplementary Figure 7 from Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway

Adrian von Witzleben, Lukas T. Goerttler, Ralf Marienfeld, Holger Barth et autres

Proliferation assay using Alamar Blue assay for U-CH2, 3, 6 and 10. Increasing concentrations of Palbociclib lead to an increase of growth inhibition of chordoma cells.